By combining in vivo and in vitro models, the present study aimed to provide a comprehensive understanding of the therapeutic potential of MRGPRX2/B2 antagonist GE1111 in LL-37-induced rosacea-like inflammation. Here, MRGPRX2 is linked to rosacea.